Several human reports exist, but most are tiny, old, short, and methodologically limited.
Why this matters
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Compound library
Experimental sleep-associated nonapeptide
DSIP
Not FDA approved
DSIP is a nine-amino-acid peptide researched for sleep and later promoted for recovery, stress, pain, and withdrawal. Its name overstates the certainty: old human insomnia studies were tiny and inconsistent, and no subcutaneous effectiveness or safety evidence was located.
Controlled human studyOther human evidenceMechanistic rationaleNo direct evidence located
Built by the community
Help strengthen the DSIP experience record
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Educational research record—not medical advice. Evidence reviewed through July 25, 2026. Peer-reviewed findings, regulatory labeling, sponsor-reported topline results, and unreported registered trials are labeled separately.
Research at a glance
DSIP in 60 seconds
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Controlled findings conflict, and no modern route-specific development program exists.
Why this matters
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
Why this matters
The strongest evidence type shows what the best-supported conclusions are actually based on.
Why this matters
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
What changes by administration method
Route studiedHistorical intravenous research exposure
Schedules studiedSingle-night and short multi-night laboratory protocols
Amounts studiedSeveral sleep studies used 25–30 nmol/kg IV; other historical IV regimens were separate or incompletely reported
Why this matters
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-lifeRapid degradation reported; useful human PK remains poorly characterized
Why this matters
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Route evidenceTiny controlled and uncontrolled human studies
Why this matters
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Old IV exposure does not establish a current clinical protocol. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Why people research it
Common goals and questions—not recommendations or promises of benefit.
- Falling asleep fasterMixed human evidence
- Staying asleep and sleep efficiencyMixed human evidence
- Deep or slow-wave sleepNot demonstrated
- Next-day alertness without hangoverEarly human evidence
- Opioid-withdrawal symptomsEarly human evidence
- Stress resilience and recoveryPreclinical only
- Pain controlPreclinical only
- Longevity, fat loss, or muscle recoveryNot demonstrated
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
The short version
What is DSIP?
DSIP is a nine-amino-acid peptide researched for sleep and later promoted for recovery, stress, pain, and withdrawal. Its name overstates the certainty: old human insomnia studies were tiny and inconsistent, and no subcutaneous effectiveness or safety evidence was located.
Old small IV human studies with conflicting sleep findings; no modern pivotal or subcutaneous programCurrent development stage
8Peer-reviewed sources
0Topline source releases
How it is designed to work
- Sleep-associated EEG effects — inconsistent across human settings
- Rapid peptide degradation in blood
- Indirect endorphin release — preclinical hypothesis
- No established direct opioid-receptor agonism
- Circadian and neuroendocrine associations — not validated treatment mechanisms
- No validated primary human therapeutic receptor
Studied research areas
Evidence checked through July 25, 2026
Evidence reviewed through July 25, 2026. Historical IV insomnia and withdrawal studies, one perioperative pharmacodynamic study, FDA's 2026 review, and the nonbinding PCAC vote are labeled separately.
What the evidence says
What we know—and what we’re still learning
What we know
A sixteen-person double-blind placebo-controlled insomnia study found no significant objective or subjective sleep-quality advantage, while a separate six-person randomized crossover study also found no significant benefit versus placebo. Positive reports were similarly small and methodologically weaker.
Why this matters
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
What we’re still learning
Whether any formulation or route produces reproducible clinically meaningful sleep benefit, and what identity-specific pharmacokinetics, interactions, immunogenicity, abuse potential, cardiovascular effects, rare harms, and long-term safety look like.
Why this matters
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
How the research changed over time
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Why this matters
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
FDA briefing document: Evaluation of emideltide-related bulk drug substances
FDA reviewed the historical insomnia and withdrawal record, found the effectiveness evidence inconclusive, and found no evidence supporting the nominated subcutaneous route.
Delta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia
DSIP increased heart rate, reduced heart-rate variability and delta rhythm, and appeared to lighten rather than deepen isoflurane anesthesia at one tested dose.
n = 24Acute awake and isoflurane-anesthesia observations
Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial
Withdrawal scores fell after the first exposure, but only two participants completed the scheduled protocol and recurrence was generally not suppressed after later exposures.
n = 7Seven-day planned course
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients
There was no significant between-group difference in objective sleep measures or subjective sleep quality; the authors described at most weak effects.
n = 16Five consecutive laboratory nights, including three treatment nights
Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs
Small numerical changes favored emideltide, but none differed significantly from baseline or placebo, and subjective sleep quality did not improve significantly.
n = 6Two nine-night periods separated by a four-day washout
Administration and handling
What official research does—and does not—provide
Historical study administration—not dosing guidance
The traceable human literature primarily used intravenous research exposure, often in sleep laboratories or inpatient withdrawal settings. FDA found no effectiveness, pharmacokinetic, or safety evidence for the nominated subcutaneous route. Historical amounts and schedules must not be converted into a personal protocol, and IV findings do not establish intranasal or subcutaneous use.
Identity, reconstitution, storage, and product quality
There is no FDA-approved DSIP label, consumer reconstitution method, or official storage instruction. FDA found inconsistent naming and characterization across emideltide free base, acetate, nominations, certificates of analysis, and marketed products. Peptide impurities, aggregation, endotoxin control, and route-specific immunogenicity remain important unresolved concerns.
Primary-source ledger
Trace every major statement
Primary source
Primary sourceFDA: Certain bulk drug substances for use in compounding that may present significant safety risks
Primary source
Primary sourceFDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
2026-07-24
Primary source
Primary sourceFDA advisory committee backs two more peptides, rejects one for compounding list
2026-07-24
Primary source
Primary sourceFDA briefing document: Evaluation of emideltide-related bulk drug substances
2026-05-11
Primary source
Primary sourceDelta sleep-inducing peptide alters bispectral index, the electroencephalogram and heart rate variability when used as an adjunct to isoflurane anaesthesia
2009-02-01 · PMID 19142086 · DOI 10.1097/EJA.0b013e32831c8644
Primary source
Primary sourceOpioid detoxification with delta sleep-inducing peptide: results of an open clinical trial
1998-06-01 · PMID 9617990 · DOI 10.1097/00004714-199806000-00016
Primary source
Primary sourceEffects of delta sleep-inducing peptide on sleep of chronic insomniac patients
1992-01-01 · PMID 1299794
Primary source
Primary sourceStudy of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs
1987-01-01 · PMID 3583493
Primary source
Primary sourceEffects of delta-sleep-inducing peptide on 24-hour sleep and waking patterns in insomnia
1987-01-01 · PMID 3622582
Primary source
Primary sourceDSIP in the treatment of withdrawal syndromes from opiates and alcohol
1984-01-01 · PMID 6548969
Primary source
Primary sourceThe influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep
1981-01-01 · PMID 7028502 · DOI 10.1007/BF01971753
Primary source
Primary sourceAcute and delayed effects of DSIP (delta sleep-inducing peptide) in man
1981-01-01 · PMID 6895513